Immunogenicity of the CoronaVac vaccine in children: a real-world study
Author Information
Author(s): Wbeimar Aguilar-Jimenez, Ana Lucia Rodriguez-Perea, Mateo Chvatal-Medina, Paula A. Velilla, Wildeman Zapata-Builes, Laura M. Monsalve-Escudero, Maria I. Zapata-Cardona, Jorge Humberto Tabares-Guevara, Daniel S. Rincón, Juan C. Hernandez, Yulied Tabares, Liliana Lopez-Carvajal, Maria T. Rugeles
Primary Institution: Universidad de Antioquia, Medellín, Colombia
Hypothesis
How effective is the CoronaVac vaccine in inducing an immune response in children aged 3-11 years?
Conclusion
The CoronaVac vaccine induces robust immune responses in children, but these responses diminish over time, especially against variants like Omicron.
Supporting Evidence
- CoronaVac was well tolerated with a low infection incidence of 7.8%.
- Most participants maintained neutralizing titers ≥20 over time.
- Robust humoral and cellular immune responses were observed against various variants.
Takeaway
The CoronaVac vaccine helps kids build strong defenses against COVID-19, but those defenses can get weaker over time, especially against new virus types.
Methodology
A prospective longitudinal cohort study with saliva and blood sample collection to evaluate immune responses in vaccinated children.
Potential Biases
Potential bias due to the inability to confirm prior infections in the Non-exposed group.
Limitations
The study could not accurately assess the Non-exposed group due to potential undocumented SARS-CoV-2 exposures.
Participant Demographics
Children aged 3-11 years, with 50 Non-Exposed and 39 Exposed to SARS-CoV-2.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website